Search

Chenodeoxycholic acid

Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. … It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.

Foreskin keratinocyte (neonatal)

The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers.

Pancrelipase protease

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.

Pramipexole

It was first approved by the FDA in 1997 [L5882]. … The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861].

Axicabtagene ciloleucel

It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. … The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer.

Rivaroxaban

However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.

Gimeracil

Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

Lithium citrate

Gepotidacin

[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.

Catumaxomab

Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.